Christopher R. Chapple

The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

Karin S. Coyne, Christopher Sexton, Christine L. Thompson et al. · British Journal of Urology · 2009 · 765 citations

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 416 citations

Urological Research, Urology, Voiding Dysfunction +6

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid et al. · European Urology · 2013 · 401 citations

Urological Research, Urology, Voiding Dysfunction +5

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

Roger R. Dmochowski, Christopher R. Chapple, Victor W. Νitti et al. · The Journal of Urology · 2010 · 397 citations

EAU Guidelines on Urinary Incontinence

Joachim W. Thüroff, Paul Abrams, Karl‐Erik Andersson et al. · European Urology · 2010 · 380 citations

Urology, Voiding Dysfunction, Pelvic Prolapse +5